Core Viewpoint - Zhengye Biology (ZYBT) experienced a significant stock price increase of 20.82%, reaching $6.5 per share, with a total market capitalization of $308 million as of August 13 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The company's net profit attributable to shareholders was 11.31 million RMB, showing a substantial decline of 64.04% year-on-year [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]
正业生物上涨20.82%，报6.5美元/股，总市值3.08亿美元